BioSpace News Archive

Supplemental Biologics License Application (sBLA) Accepted for KEYTRUDA Monotherapy in Patients Whose Tumors Are Tumor Mutational Burden-High (TMB-H) Who Have Progressed Following Prior Treatment

Lexicon Pharmaceuticals, Inc. will host its 2020 annual meeting of stockholders in a virtual format only due to the public health impact of the coronavirus pandemic and to prioritize the health and well-being of meeting participants..

IRADIMED CORPORATION announced that it expects to report first quarter 2020 revenue of $8.6 million to $8.7 million and is withdrawing its first quarter and full year 2020 financial guidance due to the uncertainty created by COVID-19.

Precision BioSciences, Inc. announced the initiation of patient dosing in a Phase 1/2a clinical trial of its second off-the-shelf chimeric antigen receptor T cell therapy candidate, PBCAR20A.

G1 Therapeutics, Inc. announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will present a company update at the 19th Annual Needham Virtual Healthcare Conference on April 14, 2020 at 2:10 p.m. ET.

panCELLa is pleased to announce that it will receive advisory services and up to $400,000 from the National Research Council of Canada Industrial Research Assistance Program to help further research and development of its technology platforms for cell therapy.

Magnolia Health, in collaboration with its parent company, Centene Corporation, has recognized Dr. Javel Granados of Desoto Children’s Clinic in Desoto, Mississippi, with a national award for clinical excellence.

Ascentage Pharma announced that it has received approval from the Center for Drug Evaluation of the China National Medical Products Administration for the Phase Ib/II study of APG-2575, the company’s novel Bcl-2‒selective inhibitor, for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

The only FDA authorized palm-sized system for COVID-19 testing enables broader use across healthcare facilities and closer to the patients with rapid results

CROMSOURCE, an international contract research organization with its global headquarters in Verona, Italy, has announced that it has initiated its first COVID-19 trial on behalf of a European pharmaceutical company.